| P | OR | 95 % CI |
---|---|---|---|
Tumor size | |||
 T1 |  | 1 |  |
 T2 | 0.186 | 0.576 | 0.255-1.304 |
 T3 | 0.544 | 0.737 | 0.275-1.975 |
 T4 | 0.015 | 0.281 | 0.101-0.779 |
Hormone receptor status | |||
 Negative |  | 1 |  |
 Positive | <0.001 | 0.224 | 0.125-0.400 |
Regimens | |||
 Cyclophosphamide, epirubicin and 5-fluorouracil |  | 1 |  |
 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin | 0.208 | 4.673 | 0.423-51.590 |
 Navelbine and epirubicin | 0.078 | 6.999 | 0.804-60.897 |
 Paclitaxel and carboplatin or paclitaxel and cisplatin | 0.003 | 27.696 | 3.131-245.030 |
Cycles | |||
 3-4 |  | 1 |  |
 1-2 | 0.500 | 0.579 | 0.118-2.834 |
 5-6 | 0.217 | 2.338 | 0.606-9.017 |